YL Biologics Ltd.

  • Corporate Profile
  • Message
  • Business Operations
  • News
  • Contact us
  • JP
  • EN

News

  • February 7, 2018 Lupin and Yoshindo’s JV - YL Biologics announces successful outcome of global Phase III study for Etanercept biosimilar in Rheumatoid Arthritis ”read more” link to press release PDF.
  • 陽進堂
  • LUPIN
  • エイワイファーマ株式会社

Copyright © 2018 YL Biologics All rights Reserved.